Evidence map›Paper›PMID 35353440›Full record

ArticlePediatric blood & cancer2022

Oncologist counseling practice and COVID-19 vaccination outcomes for patients with history of PEG-asparaginase hypersensitivity.

Sara Zarnegar-Lumley, Cosby A Stone, Christine M Smith, Laura L Hall, Kate E Luck, Grace Koo, Jessica H Plager, Elizabeth J Phillips, Debra L Friedman

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric blood & cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Sara Zarnegar-LumleyDivision of Hematology and Oncology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID https://orcid.org/0000-0002-5413-371X
Cosby A StoneDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Christine M SmithDivision of Hematology and Oncology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID https://orcid.org/0000-0001-5865-8989
Laura L HallDepartment of Pediatric Pharmacy, Pharmacology, Monroe Carell, Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, USA.
Kate E LuckDivision of Hematology and Oncology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Grace KooDepartment of Pediatric Pharmacy, Pharmacology, Monroe Carell, Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, USA.
Jessica H PlagerDepartment of Pediatric Pharmacy, Pharmacology, Monroe Carell, Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, USA.
Elizabeth J PhillipsDivision of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Debra L FriedmanDivision of Hematology and Oncology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID https://orcid.org/0000-0002-0589-4176
Vanderbilt University Medical Center · USMonroe Carell Jr. Children's Hospital · USMurdoch University · AU

Funding

Learning Health System Scholar Program at VanderbiltK12HS026395 · AHRQ · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ROTHMAN, RUSSELL L., ROUMIE, CHRISTIANNE L. · 2018 to 2022
$2.7M
AHRQ HHS K12 HS026395
6 · The paper itself

Abstract

Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an effective strategy to prevent serious coronavirus disease 2019 (COVID-19) and is important for oncology patients. mRNA-based COVID-19 vaccines are contraindicated in those with a history of severe or immediate allergy to any vaccine component, including polyethylene glycol (PEG)2000. Patients with acute lymphoblastic leukemia/lymphoma receive asparaginase conjugated to PEG5000 (PEG-ASNase) and those with PEG-ASNase-associated hypersensitivity may be unnecessarily excluded from receiving mRNA COVID-19 vaccines. We, therefore, surveyed oncologists on COVID-19 vaccine counseling practice and vaccination outcomes in COVID-19 vaccination-eligible patients and show safe receipt of mRNA vaccines despite PEG-ASNase hypersensitivity.

Indexed as

AsparaginaseCOVID-19COVID-19 VaccinesDrug HypersensitivityPolyethylene GlycolsCounselingHumansOncologistsRNA, MessengerSARS-CoV-2VaccinationAsparaginaseCOVID-19 VaccinespegaspargasePolyethylene GlycolsRNA, MessengerALLCOVID vaccineLLypegasparaginaseSARS-CoV-2 vaccination

Identifiers

PMID35353440
PMCPMC9088539
OpenAlexW4221079878

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.